BlackRock Fund Advisors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

BlackRock Fund Advisors’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$5K	Sell	2,812 -194,790	-99%	-$458K	﹤0.01%	4075
2016 Q3	$656K	Buy	197,602 +1,967	+1%	+$7.43K	﹤0.01%	3256
2016 Q2	$841K	Sell	195,635 -262,538	-57%	-$1.19M	﹤0.01%	3273
2016 Q1	$2.58M	Buy	458,173 +13,433	+3%	+$174K	﹤0.01%	3000
2015 Q4	$7.65M	Sell	444,740 -903	-0.2%	-$21.5K	﹤0.01%	2600
2015 Q3	$9.4M	Buy	445,643 +12,075	+3%	+$414K	﹤0.01%	2407
2015 Q2	$21.5M	Sell	433,568 -65,026	-13%	-$3.89M	0.01%	2070
2015 Q1	$39M	Buy	498,594 +11,894	+2%	+$738K	0.01%	1675
2014 Q4	$29.5M	Buy	486,700 +42,410	+10%	+$2.13M	0.01%	1832
2014 Q3	$18.9M	Buy	444,290 +20,231	+5%	+$1.09M	0.01%	1987
2014 Q2	$26.2M	Sell	424,059 -8,211	-2%	-$477K	0.01%	1849
2014 Q1	$28.1M	Buy	432,270 +41,357	+11%	+$2.8M	0.01%	1808
2013 Q4	$22M	Buy	390,913 +15,626	+4%	+$878K	0.01%	1939
2013 Q3	$23M	Buy	375,287 +51,500	+16%	+$3.49M	0.01%	1880
2013 Q2	$18.9M	Buy	+323,787	New	+$19.9M	0.01%	1892

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock Fund Advisors's OREX Position: Q4 2016 in Review

BlackRock Fund Advisors reduced its Orexigen Therapeutics, Inc. (OREX) stake by 99% in Q4 2016, selling an estimated $458K and leaving 2,812 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #4075.

BlackRock Fund Advisors first reported a position in OREX in Q2 2013 and has held it in 15 quarters since. The position peaked at $39M in Q1 2015. 53 funds tracked by Wall St. Rank hold OREX as of Q4 2016.

BlackRock Fund Advisors held 2,812 shares of Orexigen Therapeutics, Inc. worth $5K as of Q4 2016.
BlackRock Fund Advisors sold 194,790 Orexigen Therapeutics, Inc. shares in Q4 2016, an estimated $458K.
Orexigen Therapeutics, Inc. made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #4075 holding.
BlackRock Fund Advisors first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and has held it in 15 quarters since.
BlackRock Fund Advisors's Orexigen Therapeutics, Inc. position peaked at $39M in Q1 2015.
53 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.